Why did Axsome Therapeutics stock go up today? Street analyst bullish
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
109,400$
-4,04%
Echtzeit-Aktienkurs Axsome Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Axsome Therapeutics Inc. Aktie
BofA upgrades Axsome to neutral, cites improved outlook for MDD drug
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Axsome Therapeutics, For: Aug 15
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates....…
Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2023....…
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of 19.35% and 16.21%, respectively, for the quarter ended June 2023. Do the…
Axsome Therapeutics GAAP EPS of -$1.54 misses by $0.30, revenue of $46.01M beats by $5.06M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Total 2Q 2023 product revenue of $46.7 million...…
Form 8-K Axsome Therapeutics, For: Aug 04
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time Axsome to host…
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder....…
Form 8-K Axsome Therapeutics, For: Jul 07
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a…
Axsome (AXSM) Down on Public Offering of Common Stock
Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines....…
Form 8-K Axsome Therapeutics, For: Jun 27
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Shares of Axsome Therapeutics Fell Wednesday
The biopharmaceutical company announced a $225 million stock sale....…
Axsome Therapeutics prices discounted stock offering to raise $225M, shares fall
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Shares Drop 11% After Public Offering Prices
Axsome Therapeutics Shares Drop 11% After Public Offering Prices...…
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a…
Axsome Therapeutics to raise capital via stock offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a…
Form 8-K Axsome Therapeutics, For: Jun 22
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Where Will Axsome Therapeutics Be in 3 Years?
The stock soared more than 100% last year....…
Is Axsome Therapeutics Stock a Screaming Buy?
The biotech could be staring down an enormous commercial opportunity....…
Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?
Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might…
Axsome sees peak US sales of marketed drugs of up to $3.5B
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Axsome Therapeutics, For: Jun 13
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Axsome Therapeutics, For: Jun 02
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea Cognitive…
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines....…
Is a Victory for Its Rivals Bad News for Axsome Therapeutics?
The biopharmaceutical companys shares have soared during the past year....…
Form 10-Q Axsome Therapeutics, For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Clocks Better Than Expected Q1 Sales, Depression Drug Sees Improved Coverage
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q1 revenue of $94.6 million, consisting of net product sales of $28.6 million, license revenue…
Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2023....…
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of 80.53% and 252.03%, respectively, for the quarter ended March 2023. Do the…
Form 8-K Axsome Therapeutics, For: May 08
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
Auvelity® 1Q 2023 net product sales of $15.7 million...…
Axsome Therapeutics Q1 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
Axsome Therapeutics Stock: Bear vs. Bull
Axsome shares beat the bear market last year....…
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
Axsomes (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders....…
Could Axsome Therapeutics Stock Help You Become a Millionaire?
In the past five years, the stock has risen by nearly 2,400%....…
Better Growth Stock: Axsome vs. CRISPR Therapeutics
These companies are both in the early days of their growth stories....…
Is It Too Late to Buy Axsome Therapeutics Stock?
With two major catalysts in the rearview mirror, its easy to think that its too late....…
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 14, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time Axsome to host…
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
Macro headwinds are weighing on risk-laden biotech stocks today....…